A Multicenter, Randomized, Double-blind, Non-benzylisoxazole Propionic Acid (BIPA) Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of BR2251 Tablets in Patients With Primary Gout and Hyperuricemia
Latest Information Update: 03 Apr 2026
At a glance
- Drugs BR 2251 (Primary) ; Febuxostat
- Indications Gout; Hyperuricaemia
- Focus Therapeutic Use
- Sponsors BioRay Pharmaceutical
Most Recent Events
- 03 Apr 2026 New trial record